Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
$230.61
+0.1%
$235.49
$147.33
$251.71
$554.67B0.277.67 million shs6.97 million shs
Kenvue Inc. stock logo
KVUE
Kenvue
$17.18
-0.1%
$17.50
$14.02
$24.35
$33.00B0.5518.84 million shs23.72 million shs
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$1,006.83
-0.9%
$939.86
$623.78
$1,133.95
$956.57B0.483.54 million shs1.75 million shs
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
$45.82
-2.7%
$39.61
$35.12
$81.44
$210.21B0.7718.27 million shs13.26 million shs
7 Energy Stocks to Buy and Hold Forever Cover

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
+0.08%+3.70%-3.97%-5.24%+57.53%
Kenvue Inc. stock logo
KVUE
Kenvue
-0.23%-3.19%-1.18%-8.13%-26.16%
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
-0.80%+3.28%+9.10%-3.20%+40.58%
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
-2.76%+0.10%+16.51%-7.60%-28.76%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
$230.61
+0.1%
$235.49
$147.33
$251.71
$554.67B0.277.67 million shs6.97 million shs
Kenvue Inc. stock logo
KVUE
Kenvue
$17.18
-0.1%
$17.50
$14.02
$24.35
$33.00B0.5518.84 million shs23.72 million shs
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$1,006.83
-0.9%
$939.86
$623.78
$1,133.95
$956.57B0.483.54 million shs1.75 million shs
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
$45.82
-2.7%
$39.61
$35.12
$81.44
$210.21B0.7718.27 million shs13.26 million shs
7 Energy Stocks to Buy and Hold Forever Cover

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
+0.08%+3.70%-3.97%-5.24%+57.53%
Kenvue Inc. stock logo
KVUE
Kenvue
-0.23%-3.19%-1.18%-8.13%-26.16%
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
-0.80%+3.28%+9.10%-3.20%+40.58%
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
-2.76%+0.10%+16.51%-7.60%-28.76%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
2.74
Moderate Buy$253.049.73% Upside
Kenvue Inc. stock logo
KVUE
Kenvue
2.31
Hold$19.3312.57% Upside
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
2.87
Moderate Buy$1,218.3321.01% Upside
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
2.13
Hold$65.5643.08% Upside

Current Analyst Ratings Breakdown

Latest JNJ, KVUE, NVO, and LLY Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/13/2026
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
UpgradeHoldOutperform
5/13/2026
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
UpgradeMarket PerformOutperform$265.00
5/12/2026
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
Reiterated RatingNeutral
5/8/2026
Kenvue Inc. stock logo
KVUE
Kenvue
UpgradeHold (C-)Hold (C)
5/8/2026
Kenvue Inc. stock logo
KVUE
Kenvue
UpgradeHoldStrong-Buy
5/7/2026
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
Boost Price Target$880.00 ➝ $900.00
5/5/2026
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
Reiterated RatingBuy$1,183.00
5/4/2026
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
UpgradeBuy (B-)Buy (B)
5/4/2026
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
Reiterated RatingOutperform$1,325.00
5/4/2026
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
Boost Price TargetOverweight$1,350.00 ➝ $1,400.00
5/1/2026
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
Reiterated RatingOverweight$1,344.00
(Data available from 5/15/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
$94.19B5.89$14.13 per share16.32$33.73 per share6.84
Kenvue Inc. stock logo
KVUE
Kenvue
$15.12B2.18$1.38 per share12.46$5.53 per share3.11
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$65.18B14.55$24.92 per share40.41$33.13 per share30.39
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
$46.80B4.37$4.56 per share10.04$7.12 per share6.44
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
$26.80B$8.6526.6618.332.2621.83%32.60%13.29%7/15/2026 (Estimated)
Kenvue Inc. stock logo
KVUE
Kenvue
$1.47B$0.8520.2113.961.3010.61%20.81%8.21%N/A
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$20.64B$28.1535.7722.751.1134.98%105.77%23.76%N/A
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
$15.51B$4.2610.7613.324.1937.23%63.31%22.19%N/A

Latest JNJ, KVUE, NVO, and LLY Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/7/2026Q1 2026
Kenvue Inc. stock logo
KVUE
Kenvue
$0.27$0.32+$0.05$0.25$3.84 billion$3.91 billion
5/6/2026Q1 2026
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
$0.87$1.04+$0.17$1.69$10.86 billion$10.85 billion
4/30/2026Q1 2026
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$6.97$8.55+$1.58$8.26$17.82 billion$19.80 billion
4/14/2026Q1 2026
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
$2.68$2.70+$0.02$2.14$23.60 billion$24.06 billion
3/31/2026Q1 2026
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
N/A$1.0270N/A$1.69N/A$10.85 billion
2/17/2026Q4 2025
Kenvue Inc. stock logo
KVUE
Kenvue
$0.22$0.27+$0.05$0.17$3.68 billion$3.78 billion
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
$5.202.25%+5.25%60.12%64 Years
Kenvue Inc. stock logo
KVUE
Kenvue
$0.834.83%N/A97.65%1 Years
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$6.920.69%+15.18%24.58%11 Years
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
$1.753.82%+21.74%41.08%N/A

Latest JNJ, KVUE, NVO, and LLY Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
5/4/2026
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
quarterly$1.730.69%5/15/20265/15/20266/10/2026
4/14/2026
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
quarterly$1.342.23%5/26/20265/26/20266/9/2026
4/29/2026
Kenvue Inc. stock logo
KVUE
Kenvue
quarterly$0.20754.82%5/13/20265/13/20265/27/2026
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
0.46
1.03
0.77
Kenvue Inc. stock logo
KVUE
Kenvue
0.67
0.98
0.68
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
1.26
1.50
1.10
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
0.59
0.79
0.56

Institutional Ownership

CompanyInstitutional Ownership
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
69.55%
Kenvue Inc. stock logo
KVUE
Kenvue
97.64%
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
82.53%
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
11.54%

Insider Ownership

CompanyInsider Ownership
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
0.16%
Kenvue Inc. stock logo
KVUE
Kenvue
1.59%
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
0.14%
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
0.07%
CompanyEmployeesShares OutstandingFree FloatOptionable
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
138,2002.41 billion2.40 billionOptionable
Kenvue Inc. stock logo
KVUE
Kenvue
22,0001.92 billion1.89 billionOptionable
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
50,000941.74 million940.42 millionOptionable
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
69,5054.47 billion4.46 billionOptionable

Recent News About These Companies

Novo Nordisk: The First Fruits Of Labor
Best Healthcare Stocks to Buy in 2026
Novo Nordisk A/S (NVO) stock forecast and price target
Novo Nordisk: Why I Won't Upgrade
Omeros (OMER) Q1 2026 Earnings Transcript
Assorted pharmaceutical pills, a medicine vial, and a syringe arranged on a laboratory bench.
2 Ways to Play the Big Pharma Patent Cliff (NVO)
...
Novo Nordisk: Why A P/E Of 13 Is A Value Trap, Not A Bargain

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Johnson & Johnson stock logo

Johnson & Johnson NYSE:JNJ

$230.61 +0.19 (+0.08%)
Closing price 05/14/2026 03:59 PM Eastern
Extended Trading
$231.81 +1.20 (+0.52%)
As of 06:08 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in the interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.

Kenvue stock logo

Kenvue NYSE:KVUE

$17.18 -0.02 (-0.09%)
Closing price 05/14/2026 03:59 PM Eastern
Extended Trading
$17.19 +0.02 (+0.09%)
As of 05:41 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Kenvue Inc. operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands. The Skin Health and Beauty segment provides face and body care, hair, sun, and other care products under the Neutrogena, Aveeno, Dr.Ci:Labo, Le Petit Marseillais, Lubriderm, Rogaine, and OGX brand names. The Essential Health segment offers oral and baby, women's health, wound, and other care products under the Listerine, Johnson's, Band-Aid, and Stayfree, o.b., tampons, Carefree, and Desitin Diaper Rash brands. The company was incorporated in 2022 and is headquartered in Skillman, New Jersey.

Eli Lilly and Company stock logo

Eli Lilly and Company NYSE:LLY

$1,006.83 -8.92 (-0.88%)
Closing price 05/14/2026 03:59 PM Eastern
Extended Trading
$998.15 -8.68 (-0.86%)
As of 06:08 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio. In addition, the company offers Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis; Omvoh for ulcerative colitis; Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Ebglyss for severe atopic dermatitis; and Emgality for migraine prevention and episodic cluster headache. Further, it provides Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. It has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; F. Hoffmann-La Roche Ltd and Genentech, Inc.; Biologics, Inc., AbCellera Biologics Inc.; and Chugai Pharmaceutical Co., Ltd. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.

Novo Nordisk A/S stock logo

Novo Nordisk A/S NYSE:NVO

$45.82 -1.26 (-2.67%)
Closing price 05/14/2026 03:59 PM Eastern
Extended Trading
$44.98 -0.84 (-1.84%)
As of 06:09 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides insulin pens, growth hormone pens, and injection needles. In addition, it offers smart solutions for diabetes treatment, such as smart insulin pens and Dose Check, an insulin dose guidance application. The company has a collaboration agreement with Aspen Pharmaceuticals to produce insulin products; and with Korro Bio, Inc. for the discovery and development of new genetic medicines to treat cardiometabolic diseases. Novo Nordisk A/S was founded in 1923 and is headquartered in Bagsvaerd, Denmark.